A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT01546038

A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This is a study to evaluate PF-04449913 (an inhibitor of the Hedgehog pathway) in Acute Myeloid Leukemia and high-risk Myelodysplastic Syndrome in combination with standard agents used to treat these diseases.

Status: 
Recruiting
Study Date: 
Fri, 06/01/2012 to Thu, 09/01/2016
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
Drug: PF-04449913 PF-04449913 administered orally and continuously for 28-days. Drug: Low dose ARA-C (LDAC) Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10. Drug: PF-04449913 PF-04449913 administered orally and continuously for 28 days. Drug: Decitabine Decitabine given at 20 mg/m2 over 1 hour infusion for 5-days Drug: PF-04449913 PF-04449913 administered orally and continuously for 28 days Drug: Daunorubicin Daunorubicin given using 60 mg/m2 for 3-days Drug: Cytarabine Cytarabine 100 mg/m2 on days 1 through 7 Drug: PF-04449913 PF-04449913 administered orally and continuously for 28 days (if randomized to receive PF-04449913)